Q-omics provides the consensus-scored CRELD1 profile across patient tissues and cancer cell-line models. CRELD1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, CRELD1 is differentially expressed in 10, with the highest sampling consensus in LIHC. Additionally, CRELD1 RNA expression shows 19,349 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LUSC, LIHC, and THYM as cancer lineages where CRELD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CRELD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CRELD1 survival associations across molecular data types. CRELD1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CRELD1 RNA expression–survival associations across cancer types. High CRELD1 expression shows unfavorable associations in LUSC, OV, LGG, KIRC and HNSC, but favorable associations in UVM. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUSC as the clearest survival context for CRELD1 RNA expression.
This table summarizes CRELD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for CRELD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CRELD1 shows lower tumor expression in THCA, LUSC, KICH and BRCA and higher tumor expression in LIHC and COAD. The LIHC box plot shows higher CRELD1 RNA expression in tumor versus normal tissue (log2 FC = +1.314, t-test p < 0.001).
This table shows molecular features associated with CRELD1 in patient tissues and cancer cell lines. In patient samples, CRELD1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, CRELD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and UPPER_AERODIGESTIVE_TRACT.
